The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder

Modern Pathology

Volumn 22, Issue 1, 2009, Pages 119-127

  Reid Nicholson, Michelle D ^a   Ramalingam, Preetha ^a   Adeagbo, Bamidele ^a   Cheng, Ningli ^a   Peiper, Stephen C ^a   Terris, Martha K ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Department of Surgery   (United States)

Author keywords

Carcinoma; Non urothelial; Urovysion FISH

Indexed keywords

ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; BLADDER TUMOR; FEMALE; GENETICS; LABORATORY DIAGNOSIS; MALE; METHODOLOGY;

FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; URINARY BLADDER NEOPLASMS;

EID: 58149174082     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.179     Document Type: Article

References (34)

1. Lopez-Beltran A, Sauter G, Gasser T, et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital System, 1st edn. IARC Press: Lyon, France, 2004, pp 93-109.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Kakizoe T. Development and progression of urothelial carcinoma. Cancer Sci 2006;97:821-828.
4. Grignon DJ, El-Bolkainy M, Schimitz-Drager BJ, et al. Squamous cell carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital System, 1st edn. IARC Press: Lyon, France, 2004, pp 124-129.
5. Guo CC, Fine SW, Epstein JI. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. Am J Surg Pathol 2006;30:883-891.
6. Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 2007;31:1777-1787.
7. Ayala AG, Tamboli P, El-Bolkainy MN, et al. Adenocarcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital System, 1st edn. IARC Press: Lyon, France, 2004, pp 128-130.
8. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775.
9. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol 2003;13:351-355.
10. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995;48:314-317.
11. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-394.
12. Saad A, Hanbury DC, McNicholas TA, et al. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-373.
13. Bastacky S, Ibrahim S, Wilczynski SP. The accuracy of urinary cytology in daily practice. Cancer 1999;87:118-128.
14. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-2105.
15. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167:2001-2006.
16. Halling KC. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507-519.
17. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-123.
18. US Food and Drug Administration Center for Devices and Radiological Health. New Device Approval: Uro-vysion™ Bladder Cancer: P030052. January 24, 2005.
19. Daniely M, Rona R, Kaplan T, et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 2007;111:517-524.
20. Bollmann M, Heller H, Bankfalvi A, et al. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005;95:1219-1225.
21. Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.
22. Bergman J, Reznichek RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int 2008;101:26-29.
23. Sugano K, Kakizoe T. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat Clin Pract Urol 2006;3:642-652.
24. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-5564.
25. Quek ML, Sanderson K, Daneshmand S, et al. New molecular markers for bladder cancer detection. Curr Opin Urol 2004;14:259-264.
26. Veeramachaneni R, Nordberg ML, Shi R, et al. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 2003;28:301-307.
27. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295-301.
28. Pycha A, Mian C, Posch B, et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators? Urology 1999;53:1005-1010.
29. Pycha A, Mian C, Posch B, et al. Numerical aberrations of chromosomes 7, 9 and 17 in squamous cell and transitional cell cancer of the bladder: a comparative study performed by fluorescence in situ hybridization. J Urol 1998;160:737-740.
30. Sawai T, Sasano O, Tsuji T, et al. Chromosome instability evaluated by fluorescence in situ hybridization in hereditary non-polyposis colorectal cancer. J Gastroenterol 1998;33:495-499.
31. Sawai T, Sasano O, Tsuji T, et al. [Numerical aberration of chromosome 17 is correlated with multiple primary cancer in colorectal carcinoma]. Nippon Shokakibyo Gakkai Zasshi 1997;94:464-468.
32. Visakorpi T, Hyytinen E, Kallioniemi A, et al. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 1994;145:624-630.
33. Das K, Lau W, Sivaswaren C, et al. Chromosomal changes in prostate cancer: a fluorescence in situ hybridization study. Clin Genet 2005;68:40-47.
34. Varma VA, Fekete PS, Franks MJ, et al. Cytologic features of prostatic adenocarcinoma in urine: a clinicopathologic and immunocytochemical study. Diagn Cytopathol 1988;4:300-305.